Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Rituximab is widely used as a second-line therapy for pediatric immune thrombocytopenia (ITP), yet approximately 40% of patients do not respond. The biological determinants of non-response are heterogeneous and incompletely understood. This exploratory study aimed to characterize baseline immune profiles associated with rituximab non-response and to generate hypotheses regarding the underlying mechanisms.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.